Semaglutide and Dapagliflozin Combination Trial Compares Renal Outcomes in Obese Kidney Disease Patients
Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease
Abstract
A non-blinded RCT is comparing semaglutide and dapagliflozin, alone and combined, for changes in 24-hour urinary protein and renal function in obese patients with kidney disease.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
